Value, Affordability, and Decision Making
Efficient allocation of healthcare budgets requires a clear understanding of whether interventions deliver good value for money. Resource-allocation decisions should therefore follow structured, transparent, and evidence-based processes that consider value, equity, and affordability.
OHE advances innovative methodologies and drives international, policy-focused research to address these core dimensions . We provide evidence in support of robust, systematic, and comprehensive value assessments within healthcare systems, including Health Technology Assessment (HTA), and across other sectors.
Overall purpose of this research theme
To support systematic, fair, and evidence-based decision-making processes for resource allocation in healthcare.
Policy objectives
- Advance the development of novel value frameworks.
- Inform HTA methods and processes.
- Guide the purpose and role of HTA.
- Strengthen knowledge transfer and guidance for decision-makers.
Around the World in HTAs
Around the World in HTA: Japan – An algorithmic approach to containing costs
Japan’s health technology assessment (HTA) system uses algorithmic drug pricing and cost-effectiveness analysis to manage rising healthcare costs while maintaining universal access and innovation.
Read more
Around The World in HTAs: France – Three Core HTA Values
In the latest edition of our Insights series, Around the World in HTAs, we explore the HTA system in France. A special thanks to Salah Ghabri for his valuable support to write this note.
Read more
Around the World in HTAs: Saudi Arabia – Navigating the healthcare and HTA landscape
Saudi Arabia’s healthcare system is undergoing major transformation under Vision 2030, reshaping regulation, funding and delivery models across the Kingdom. The introduction of a formal health technology assessment (HTA) framework and evolving reimbursement pathways are central to improving access to value-based healthcare.
Read more
Around the world in HTAs: Argentina – Long Road to Institutionalizing HTA
In this Insights series, Around the World in HTAs, we shed light on HTA around the world. In this edition, Andrés Pichon-Riviere, Federico Augustovski, and Martina Garau take us to Argentina.
Read moreOur latest content on this theme
Around the World in HTA: Japan – An algorithmic approach to containing costs
Japan’s health technology assessment (HTA) system uses algorithmic drug pricing and cost-effectiveness analysis to manage rising healthcare costs while maintaining universal access and innovation.
Around The World in HTAs: France – Three Core HTA Values
In the latest edition of our Insights series, Around the World in HTAs, we explore the HTA system in France. A special thanks to Salah Ghabri for his valuable support to write this note.
Novel devices: optimising drug delivery in multiple myeloma
Biologics: Driving innovation in the treatment of multiple myeloma Biological medicines (biologics) have transformed the treatment landscape of multiple myeloma and cancer as a whole. The…
A global landscape analysis of access to tumour-agnostic therapies
Tumour-agnostic (TA) therapies represent a paradigm shift in oncology by targeting molecular alterations regardless of tumour histology.